Detlef Schuppan

Dr. Detlef Schuppan

Harvard Medical School

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DSDetlef Schuppan
Detlef Schuppan
YKYong Ook Kim
Yong Ook Kim
Fibrosis is an intrinsic response to chronic injury, maintaining organ integrity when extensive necrosis or apoptosis occurs. With protracted damage, fibrosis can progress toward excessive scarring and organ failure, as in liver cirrhosis. To date, antifibrotic treatment of fibrosis represents an unconquered area for drug development, with enormous potential but also high risks. Preclinical research has yielded numerous targets for antifibrotic agents, some of which have entered early-phase clinical studies, but progress has been hampered due to the relative lack of sensitive and specific biomarkers to measure fibrosis progression or reversal. Here we focus on antifibrotic approaches for liver that address specific cell types and functional units that orchestrate fibrotic wound healing responses and have a sound preclinical database or antifibrotic activity in early clinical trials. We also touch upon relevant clinical study endpoints, optimal study design, and developments in fibrosis imaging and biomarkers.

18 June 2015 in Nutrients
Verified
Journal Article
Open access
PDF file
Carlo CatassiCarlo Catassi
Carlo Catassi
Luca ElliLuca Elli
Luca Elli
BBBruno Bonaz
Bruno Bonaz
GBGerd Bouma
Gerd Bouma
ACAntonio Carroccio
Antonio Carroccio
Alessio FasanoAlessio Fasano
Alessio Fasano
Non-Celiac Gluten Sensitivity (NCGS) is a syndrome characterized by intestinal and extra-intestinal symptoms related to the ingestion of gluten-containing food, in subjects that are not affected by either celiac disease or wheat allergy. Given the lack of a NCGS biomarker, there is the need for standardizing the procedure leading to the diagnosis confirmation. In this paper we report experts’ recommendations on how the diagnostic protocol should be performed for the confirmation of NCGS. A full diagnostic procedure should assess the clinical response to the gluten-free diet (GFD) and measure the effect of a gluten challenge after a period of treatment with the GFD. The clinical evaluation is performed using a self-administered instrument incorporating a modified version of the Gastrointestinal Symptom Rating Scale. The patient identifies one to three main symptoms that are quantitatively assessed using a Numerical Rating Scale with a score ranging from 1 to 10. The double-blind placebo-controlled gluten challenge (8 g/day) includes a one-week challenge followed by a one-week washout of strict GFD and by the crossover to the second one-week challenge. The vehicle should contain cooked, homogeneously distributed gluten. At least a variation of 30% of one to three main symptoms between the gluten and the placebo challenge should be detected to discriminate a positive from a negative result. The guidelines provided in this paper will help the clinician to reach a firm and positive diagnosis of NCGS and facilitate the comparisons of different studies, if adopted internationally.

12 June 2024 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
Michele VaccaMichele Vacca
Michele Vacca
IKIoannis Kamzolas
Ioannis Kamzolas
LHLea Mørch Harder
Lea Mørch Harder
FOFiona Oakley
Fiona Oakley
CTChristian Trautwein
Christian Trautwein
AVAntonio Vidal-Puig
Antonio Vidal-Puig
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, encompasses steatosis and metabolic dysfunction-associated steatohepatitis (MASH), leading to cirrhosis and hepatocellular carcinoma. Preclinical MASLD research is mainly performed in rodents; however, the model that best recapitulates human disease is yet to be defined. We conducted a wide-ranging retrospective review (metabolic phenotype, liver histopathology, transcriptome benchmarked against humans) of murine models (mostly male) and ranked them using an unbiased MASLD ‘human proximity score’ to define their metabolic relevance and ability to induce MASH-fibrosis. Here, we show that Western diets align closely with human MASH; high cholesterol content, extended study duration and/or genetic manipulation of disease-promoting pathways are required to intensify liver damage and accelerate significant (F2+) fibrosis development. Choline-deficient models rapidly induce MASH-fibrosis while showing relatively poor translatability. Our ranking of commonly used MASLD models, based on their proximity to human MASLD, helps with the selection of appropriate in vivo models to accelerate preclinical research.

1 April 2017 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
VZVictor F. Zevallos
Victor F. Zevallos
VRVerena Raker
Verena Raker
STStefan Tenzer
Stefan Tenzer
CJCarolina Jimenez-Calvente
Carolina Jimenez-Calvente
MAMuhammad Ashfaq-Khan
Muhammad Ashfaq-Khan
DSDetlef Schuppan
Detlef Schuppan

16 March 2020 in Hepatology
Verified
Journal Article
Closed access
PDF file
WCWei Chen
Wei Chen
AYAiting Yang
Aiting Yang
JJJidong Jia
Jidong Jia
YPYury V. Popov
Yury V. Popov
DSDetlef Schuppan
Detlef Schuppan
HYHong You
Hong You

15 July 2013 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
DSDetlef Schuppan
Detlef Schuppan
JSJörn M. Schattenberg
Jörn M. Schattenberg